No abstract

Nanofiber-based triboelectric nanogenerators (TENGs) have garnered increasing attention as the multifunctional power source in wearable electronics. However, most traditional wearable device-based TENGs are unable to simultaneously achieve excellent outputs and multifunctional properties. Here, we design a waterproof, breathable, UV-protective TENG based on a poly(vinylidene fluoride) (PVDF)/poly(dimethylsiloxane) (PDMS)/TiO2 nanofiber film for effective harvesting mechanical energy by a simple and low-cost combined electrospinning/electrospray method. The introduction of PVDF can overcome the synthesis puzzle of PDMS nanofibers during the electrospinning process. With numerous three-dimensional micro-to-nano hierarchical pores of a nanofiber network, the constructed TENG can furnish large specific surface area and good breathability. The addition of TiO2 nanoparticles (NPs) increases the dielectric constant and surface roughness of the PVDF/PDMS/TiO2 nanofiber film as well as the corresponding output performance of the nanofiber-based TENG. The as-presented TENG has a maximum peak power density of 0.72 W/m2 and excellent breathability (18.6 mm/s). Due to the UV radiation absorbed by the TiO2 NPs, the UVA transmittance (T UVA) of the TENG with 4% TiO2 NPs is decreased to only 8.2%. The constructed TENG can be integrated to monitor human physiological signals in a self-powered manner. The nanofiber-based TENG provides a version to render these suitable for the daily-used wearable or portable electronics shortly.

Li et al: Edaravone in Combination with Dihydropyridine Calcium Ion AntagonistThis research article planned to investigate the efficacy of edaravone in combination with dihydropyridine calcium ion antagonist on hypertensive intracerebral hemorrhage. Between February 2017 and January 2019, we collected the clinical data from 126 hypertensive intracerebral hemorrhage patients and divided them into the control group and observation group, with 63 patients in each group. Patients in two groups all underwent the regular treatment, while those in the observation group took edaravone in combination with dihydropyridine calcium ion antagonist (nimodipine) for treatment. Following the treatment, we compared the clinical efficacy, plasmin endothelin 1, volume of edema and hematoma and National Institute of Health stroke scale scores. In the control group, the total effectiveness rate of treatment was 71.44 %, significantly lower than that of the observation group (p<0.05); following treatment, the level of endothelin 1 in plasma and the volumes of edema and hematoma were all decreased as compared to those before treatment and the decrease in the observation group was more evident (p<0.01). Before treatment, difference in the National Institute of Health stroke scale scores between the control group and the observation group was not evident (p>0.05), while after 2 and 4 w of treatment, patients in the observation group had scores of (12.43±4.07) and (7.52±1.84) points, significantly higher than those in the control group (p<0.01). Combined medication of edaravone and dihydropyridine calcium ion antagonist can benefit the patients with promising efficacy and improvement in nervous function.

No abstract